An case report on the association of ADHD symptoms and bulimic behaviors. 99 subjects participated in this study.

A report on 8 patients diagnosed with bulimia nervosa, and were given methyl amphetamine or placebo to treat their symptoms. The methyl amphetamine proved to be useful to reduce the amount of food eaten, and self-induced vomiting.

Discusses the methodology in which the drugs in question (amantadine, dextroamphetamine, d-fenfluramine, famotidine, fluoxetine) are all drivers towards weight loss when administered on a constant schedule over a medium-term regimen. Placebo tests concluded that weight loss was a directly correlated to the administered drugs, by way of systematic shifts in the way the subject views the necessity to eat.

A case report of 6 patients that had comorbid bulimia and ADHD and were treated with the medication, dextroamphetamine. The report shows that the medication was useful for all six patients, and decreased their desire to binge eat. All six patients stayed in a healthy weight range.

A clinical trial in which binge-eating was treated with topiramate. This is relevant since the patent lists topiramate as an active agent

A review of a number of different drugs used to treat binge eating disorder, including desipramine, fluvoxamine, fluoxetine, sertraline, citalopram, dexfenfluramine, sibutramine, and topiramate. Most of these drugs are listed as additional active agents in the claims of the patent.

A study on the treatment of binge eating disorder and obesity using orlistat. Orlistat is one of the active agents listed in the patent to be administered along with the amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog in the treatment.

A study on the treatment of binge eating disorder using zonisamide. Zonisamide is one of the active agents listed in the patent to be administered along with the amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog in the treatment.

A study on the treatment of binge eating disorder and obesity using topiramate. Topiramate is one of the active agents listed in the patent to be administered along with the amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog in the treatment.

This case described the beneficial effect on the binge eating component of bulimia nervosa of methylphenidate, which was prescribed to treat comorbid attention-deficit/hyperactivity disorder. Possible mechanisms of action are discussed

This talks about a treatment for bulimia nervosa, which is related to binge eating, except that in bulimia nervosa, binges are followed by purging. The authors of this page did 2 case studies prescribing methylphenidates to two women. Both patients responded to MPH, reporting significant reduction in binge and purge frequency and ADHD-like symptoms, as shown by the decrease in Conners scores.

This is a patent that uses topiramate, a sulfamate derivatives to treat Impulse Control Disorders (ICD's), including Binge Eating Disorder. According to claims 8 and 15 of McElroy’s patent, a therapeutically effective amount of topiramate in conjunction with a psychostimulant, in which amphetamine and methylphenidate are both listed, can help treat Binge eating disorder.

Patent for lisdexamfetamine dimesylate, which was orginally assigned to New River Pharmaceuticals Inc.(but is now owned by Shire who acquired New River Pharmaceticals).

This article describes how methylphenidate and its analogs, derivatives, and prodrugs can be used to treat obesity.

Benzphetamine (amphetamine prodrug and anorexic drug) has been used as a treatment for obesity since it was approved by the FDA in 1960. In a double blind study, it was found to that there were no differences in weight loss for patients receiving Benzphetamine and D-Amphetamine. Lisdexamphetamine is a D-Amphetamine derivative.

The reference discloses the efficacy of a claimed amphetamine substance for treating ADHD - which is mentioned in the subject patent app along with eating disorders. A complete medical journal article is cited for additional information.